Previous Close | 8.45 |
Open | 8.43 |
Bid | 8.48 x 4000 |
Ask | 8.50 x 1100 |
Day's Range | 8.26 - 8.50 |
52 Week Range | 7.23 - 11.55 |
Volume | |
Avg. Volume | 9,047,208 |
Market Cap | 9.4B |
Beta (5Y Monthly) | 1.18 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.56 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Nov 27, 2017 |
1y Target Est | 10.17 |
Subscribe to Yahoo Finance Plus to view Fair Value for TEVA
TEL AVIV, Israel & PARSIPPANY, N.J., May 23, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new efficacy and safety data from a 3-year open-label extension (OLE) study on AUSTEDO® (deutetrabenazine) tablets in postmenopausal women with tardive dyskinesia (TD). These data will be presented at the 2022 American Psychiatric Association (APA) Annual Meeting, held May 21-25 in New Orleans and online June 7-10. In addition, ne
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder. ProAir Digihaler is a breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record, and store objective data. 89% (319/359) of patients met the consensus threshold of SABA reliever medication use, and 72% (260/359) met the threshold
AMSTERDAM, May 17, 2022--Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia®, a biosimilar to Lucentis® (ranibizumab ), an eye injection. The United Kingdom is the first country in Europe to authorize commercialization of Ongavia® for the treatment of neovascular (wet) age-related macular degeneration ("AMD"). Ongavia® is also licenced for: the treatment of visual impairment due to diabetic macular oedema (DM